Embark on the First of Two Fantasy Life Updates in Mabinogi’s Winter Season
18.11.2022 01:31:00 EET | Business Wire | Press release
Mabinogi , Nexon’s free-to-play fantasy MMORPG, begins the winter season with two meaningful events. Entitled “NEXT,” these two-part game updates include overhauled character growth, faster and more convenient leveling, plus revised tutorials and UI improvements during November, and the introduction of Arcana talents in December!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117006144/en/
Mabinogi, Nexon America's fantasy life MMORPG (Graphic: Business Wire)
Blaanid, the eager Memory Spirit, has prepared a new tutorial for all Milletians, making leveling and questing in Mabinogi faster overall! And Memoir Quests have been changed to now reward you for completing Generation quests. In Mabinogi's Masterpiece Update, Original Generation 1-3 Questline has been revamped to provide a friendly experience for new players as well as the ability to replay the quests for existing players. Mabinogi players new and old will find the starting experience even more user friendly! These updates, along with other elements such as Dan Advancement test improvements, and balance changes to Renown, Grandmaster, and Crusader skills are designed to drastically improve the early to mid-game leveling experience for all Milletians.
Memoir Rewards
-
Comfortable Growth - The perfect path to growth is Blaanid’s Brave Boost, which will grant you:
- Skills trained by Talent
- Upgraded and Reforged Memorial weapons
- Pet & Doll Bag Support
- and more!
-
Essential Skills & Benefits - Blaanid prepared even more gifts for new Milletians!
-
Your stats are increased as each Memoir Book is completed.
- Recall Book Stage 1~4
- Movement Speed +2%~8%
- All Stats +1~4
- Additional +1~4 AP at Rebirth!
-
Your stats are increased as each Memoir Book is completed.
Memorial Link
-
You can obtain this skill by completing the 2nd Memoir Book in Blaanid’s Brave Boost quests!
- Skill allows a soul connection with pets
- Pets can be used to draw enemy aggro
- As pets increase in level and skill, pets and player Defense and Protection stats increase proportionally
In addition to the above improvements, Quests have been reorganized, only displaying essential quests now, and skill training has also been improved - less training points are required and more EXP is earned to quickly achieve high ranked skills. Lastly, Mabinogi has removed CP Training, meaning monster levels are no longer relevant for your training requirements. Other changes, such as teleporting to Moon Gate and Mana Tunnels, were improved in this update to make it more convenient for new and returning players to traverse the world map.
In part two of the “NEXT” update coming in December, Mabinogi unveils a new pair of Hybrid Talents, merging two talent styles into a single devastating package! Get ready to experience the almighty power of the Elemental Knight or the soulful skill of the Harmonic Saint when the Arcana update arrives later in December!
These reasons, and many more, are why your “NEXT” MMORPG should be Mabinogi!
For more information on Mabinogi, visit the official website and follow @MabiOfficial on Twitter for the latest updates.
Assets: Image
Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord
About Mabinogi http://mabinogi.nexon.net/
Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117006144/en/
Contact information
Media Contact for Western Region
Brian Klotz
Nexon America
NA_pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
